Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) With or Without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer

NCT03525262 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT03525262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03525262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) With or Without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 24, 2018
Completion date
April 30, 2029
Enrollment
124 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer adenocarcinoma